Skip to main content
Colin Howden, MD, Gastroenterology, Memphis, TN, Methodist Healthcare Memphis Hospitals

ColinHowdenMD

Gastroenterology Memphis, TN

Esophagus Disease, Gastrointestinal Functional & Motility Disorders

Professor in Medicine-Gastroenterology and Hepatology, Northwestern University Medical School

Dr. Howden is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Howden's full profile

Already have an account?

Education & Training

  • University of Glasgow Faculty of Medicine
    University of Glasgow Faculty of MedicineClass of 1978

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 2014 - 2024
  • IL State Medical License
    IL State Medical License 1998 - 2017
  • SC State Medical License
    SC State Medical License 1994 - 2000
  • American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
  • Fellow (AGAF) American Gastroenterological Association, 2007
  • Fellow (FACG) American College of Gastroenterology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • H. Pylori and Barrett’s Esophagus: Implications for Populations and Practice  
    Colin Howden, MD, Nature
  • Correction: ACG Clinical Guideline: Treatment of Helicobacter Pylori Infection  
    Colin W Howden, Steven F Moss, Nature

Press Mentions

  • RedHill Biopharma Presents New Talicia and Movantik Data Analyses at ACG 2021
    RedHill Biopharma Presents New Talicia and Movantik Data Analyses at ACG 2021October 25th, 2021
  • Review Article: The Pharmacological Causes of Colon Ischaemia
    Review Article: The Pharmacological Causes of Colon IschaemiaNovember 22nd, 2019
  • FDA Approves RedHill’s Drug for Cancer-Causing H. Pylori Bacterial Infections
    FDA Approves RedHill’s Drug for Cancer-Causing H. Pylori Bacterial InfectionsNovember 4th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations